Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)

Hyeon-Seok Eom; Yeo-Kyeoung Kim; Joo-Seop Chung; Kihyun Kim; Hyo Jung Kim; Ho Young Kim; Jong-Youl Jin; Young-Rok Do; Suk-Joong Oh; Cheolwon Suh; Chu-Myong Seong; Chul Soo Kim; Dong Soon Lee; Jae Hoon Lee
May 2010
Annals of Hematology;May2010, Vol. 89 Issue 5, p489
Academic Journal
Bortezomib (VELCADE®), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy, are highly effective in patients with multiple myeloma. We evaluated the responses and survival times of 35 patients treated with VTD followed by MPT. All patients were newly diagnosed and non-transplantation candidates. Patients received six cycles of VTD, which were followed by eight cycles of MPT. Approximately 97% of patients exhibited early responses to therapy, as early as the second cycle of VTD. Thirty percent of the responses were high quality, which was defined as a complete response (CR), a near-CR or a very good partial response. High-risk patients were defined as patients with any of the following aberrations: del(13), t(4;14), or del(17p). The remaining patients were defined as standard risk. Eleven high-risk patients showed 100% response rates, including 91% high-quality responses. In contrast, 13 standard-risk patients exhibited 92% response rates, including 61% high-quality responses. The overall 2-year survival rates were 60% in high-risk patients and 85% in standard-risk patients, which was not significantly different. As a first-line therapy, VTD followed by MPT has the potential to provide high-quality responses with durable remission among elderly and high-risk patients (clinicaltrials.gov identifier: NCT00320476).


Related Articles

  • Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the intergroupe francophone du myélome (IFM). Yakoub-Agha, Ibrahim; Attal, Michel; Dumontet, Charles; Delannoy, Valerie; Moreau, Phillipe; Berthou, Christian; Lamy, Thierney; Grosbois, Bernard; Dauriac, Charley; Dorvaux, Veronique; Bay, Jacque-Olivier; Monconduit, Matthieu; Harousseau, Jean Luc; Duguet, Corrine; Duhamel, Alain; Facon, Thierry // Hematology Journal;2002, Vol. 3 Issue 4, p185 

    Background: To evaluate treatment by thalidomide and identify predictive factors of survival, event free survival and response among patients with advanced multiple myeloma treated with thalidomide as single agent therapy. Patients and treatment: Patients with advanced multiple myeloma (n = 83)...

  • Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients. Kim, Kihyun; Kim, Seok; Voelter, Verena; Suh, Cheolwon; Yoon, Sung-Soo; Lee, Je-Jung; Kwak, Jae-Yong; Ryoo, Hun-Mo; Kim, Yang; Moon, Joon; Park, Seong; Kim, Sung-Hyun; Mun, Yeung-Chul; Kim, Jin; Eom, Hyeon-Seok; Jo, Deog-Yeon; Jun, Hyun; Kim, Ki-Hwan; Lee, Jeong-Ok; Lee, Jae // Annals of Hematology;Jan2014, Vol. 93 Issue 1, p113 

    We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not...

  • Thalidomide Use: Past History and Current Implications for Practice. Goldman, Deborah A. // Oncology Nursing Forum;Apr2001, Vol. 28 Issue 3, p471 

    Purpose/Objectives: To review the history of thalidomide, examine fears emanating from its renewed usage, and discuss the nurse's critical role in patient education. Data Sources: Published articles, abstracts, books, and clinical experience. Data Synthesis: In the early 1960s, the teratogenic...

  • The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma. Messori, Andrea; Maratea, Dario; Nozzoli, Chiara; Bosi, Alberto // PharmacoEconomics;2011, Vol. 29 Issue 4, p269 

    Bortezomib, thalidomide and lenalidomide can be aimed at treating patients with newly diagnosed multiple myeloma (both eligible and ineligible for transplantation) as well as those with relapsed or refractory disease. This review analysed the available clinical and economic data on these three...

  • Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. Barlogie, Bart; Tricot, Guido; Anaissie, Elias; Shaughnessy, John; Rasmussen, Erik; van Rhee, Frits; Fassas, Athanasios; Zangari, Maurizio; Hollmig, Klaus; Pineda-Roman, Mauricio; Lee, Choon; Talamo, Giampaolo; Thertulien, Raymond; Kiwan, Elias; Krishna, Somashekar; Fox, Michele; Crowley, John // New England Journal of Medicine;3/9/2006, Vol. 354 Issue 10, p1021 

    Background: High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival. Methods: Between October 1998 and February 2004,...

  • A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Rousselot, P.; Larghero, J.; Arnulf, B.; Poupon, J.; Royer, B.; Tibi, A.; Madelaine-chambrin, I.; Cimerman, P.; Chevret, S.; Hermine, O.; Dombret, H.; Brouet, J. Claude; Fermand, J. Paul // Leukemia (08876924);Sep2004, Vol. 18 Issue 9, p1518 

    We previously showed that arsenic trioxide (ATO) and melarsoprol may inhibit the growth of multiple myeloma (MM) cells in vitro and in vivo. We report here the administration of arsenic derivatives in 12 relapsing or refractory secretory MM patients. A total of 10 patients received ATO (eight in...

  • VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. K Zervas; D Mihou; E Katodritou; A Pouli; CH Mitsouli; A Anagnostopoulos; S Delibasi; MC Kyrtsonis; N Anagnostopoulos; E Terpos; P Zikos; A Maniatis; MA Dimopoulos; On behalf of the Greek Myeloma Study Group // Annals of Oncology;Aug2007, Vol. 18 Issue 8, p1369 

    Background: We have previously demonstrated that vincristine, liposomal doxorubicin and dexamethasone (VAD-doxil) is equally effective with VAD-bolus yielding objective response rates of 61% as first-line treatment in multiple myeloma (MM). In a phase II study, the addition of thalidomide to...

  • Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Klein, Ulrike; Kosely, Florentina; Hillengaß, Jens; Hundemer, Michael; Schmitt, Stefan; Neben, Kai; Moehler, Thomas; Hegenbart, Ute; Ho, Anthony; Goldschmidt, Hartmut // Annals of Hematology;Jan2009, Vol. 88 Issue 1, p67 

    The immunomodulatory drugs thalidomide and lenalidomide have enhanced activity in patients with multiple myeloma (MM). Their efficacy is increased with the addition of dexamethasone, but significant rates of venous thromboembolism (VTE) are a severe side effect. Based on this evidence, it is...

  • CITATIONS AND CLINICIANS' NOTES: THERAPEUTICS.  // Current Medical Literature: Dermatology;2005, Vol. 10 Issue 3, p59 

    Presents citations and clinician's notes on therapeutics. Treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis; Improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumor necrosis factor-α inhibitor; Use of thalidomide...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics